相关实验视频

Updated: Jun 17, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

用ROS触发的微凝用于可编程的药物释放在体积肌肉损失修复中

Seungjun Lee¹, Goeun Choe¹, Junghyun Kim¹

¹School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, Republic of Korea.

Advanced healthcare materials

|October 6, 2025

概括

减少含有石墨烯的氨酸微凝 (rGHMs) 为体积肌肉损失 (VML) 提供了一个有前途的治疗方法. 这些微凝在响应活性氧物种 (ROS) 时提供黄素,增强肌肉再生和力量恢复.

科学领域:

生物材料科学生物材料科学
再生医学是一种再生医学.
组织工程是组织工程.

背景情况:

体积肌肉损失 (VML) 会导致显著的肌肉枯竭和纤维化,阻碍有效的再生.
目前对VML的治疗方法在促进大量肌肉修复和功能恢复方面面临挑战.
反应性氧物种 (ROS) 在VML中起着双重作用,有助于损伤,但也为修复发出信号.

研究的目的:

开发用于VML治疗的含有石墨烯的多功能减少氨酸微凝 (rGHMs).
创建一个平台,用于ROS清理和ROS响应的黄素输送.
在VML小鼠模型中评估rGHM在促进骨肌肉再生方面的疗效.

主要方法:

使用油中的水乳液和化学还原合成了rGHM.
含有黄素的rGHM (Cur/rGHM) 具有抗氧化能力,药物负载和ROS触发的释放.
实验室细胞兼容性和ROS保护试验使用C2C12神经细胞进行.
在体内研究涉及将Cur/rGHMs植入小鼠VML模型,以评估肌肉再生,强度,纤维化,血管化和炎症.

主要成果:

rGHM 呈现出优异的 ROS 清除和控制的黄素释放,以应对 ROS (2.6 倍增加与 H2O2).
实验室研究表明,rGHM是细胞相容的,并保护神经质细胞免受ROS诱导的损伤.
在体内,Cur/rGHMs显著改善了肌肉再生,实现了89.0%的力量恢复,51.0%的纤维化减少,以及血管化增加了2.3倍.
治疗减轻了炎症性巨细胞透和增加了中心核肌纤维.

结论:

在VML治疗中,rGHM作为有效的ROS响应药物输送载体.
通过rGHM进行编程的黄素输送促进了显著的骨肌肉再生和功能恢复.
这种ROS响应的微凝平台为VML提供了一个有前途的治疗策略.

关键词:

库尔库明是一种黄素.石墨烯氧化物石墨烯氧化物氨酸是什么? 氨酸是什么?微凝是一种微凝.大量的肌肉损失.

更多相关视频

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

Published on: October 4, 2017

In Vivo Functional Assessment of Rat Masseter Muscle Following Surgical Creation of a Volumetric Muscle Loss (VML) Injury

In Vivo Functional Assessment of Rat Masseter Muscle Following Surgical Creation of a Volumetric Muscle Loss (VML) Injury

Published on: November 15, 2024

相关概念视频

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...